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Atopic dermatitis (AD) is a prevalent inflammatory skin disease. Loss-of-function mutations in filaggrin gene 
(FLG) represent the strongest genetic risk factors for AD, being strongly associated with early disease onset 
and persistence into adulthood.1 The epidermis of individuals with mutations in FLG is fundamentally different 
from normal skin being characterized by increased penetration of allergens.2  
 
Recent birth cohort studies showed a significant interaction between cat ownership at birth and mutations in 
FLG (R501X, 2282del4) on the development of early-onset AD.3 This finding was replicated for the 2282del4 
FLG mutation in a Dutch cohort study, and extended to further associate with risk of allergic sensitization.4 
We performed analyses in multiple birth cohorts to examine the consistency and overall strength of the 
previously observed interaction.  
 
Materials and methods 
 
Cohorts, exposures, genotypes and phenotypes 
Consortium collaborators were invited to participate in the study, 5 and 13 birth cohorts provided data on cat 
exposure,  AD, and filaggrin mutations (Table 1 and Supplementary Table 1+2). All cohorts had information 
on the most common mutations in FLG, R501X and 2282del4, and the majority also had information on 
R2447X and S3247X (Table 1). Heterozygous, compound heterozygous and homozygous FLG mutation 
carriers were pooled as mutation carriers. Cat ownership/exposure was based on questionnaires or interviews. 
AD diagnoses were based on questionnaires in 11 cohorts, and by physician examination in 3 cohorts 
(COPSAC2000, COPSAC2010 and MAAS). For further details, please see supplementary information online.  
 
Statistical analysis and outcomes 
The predetermined primary outcome was AD onset before one year of age (‘ADearly’).Secondary outcomes 
included i) current AD at seven years of age or the year of assessment closest to, but before, 7 years (‘ADcurrent’), 
and ii) a history of AD during the first 7 years of life, or last year of assessment (ADever). For further details, 






A total of 22,133 children were studied (Table 1 and supplementary Table 1). The median prevalence (range) 
of mutations in FLG was 9.4% (4.6-12.3), cat exposure 15% (7.9-29.6), ADearly), ADcurrent, and ADever, 
respectively, 18% (9.7-34.6), 13.9% (3.9-20), and 39.5% (20.4-67). There was no interaction between FLG 
mutations and cat exposure on the risk of the primary outcome ‘ADearly’ (OR 1.10 (95% CI 0.86-1.43), I2% 
0.0), (Figure 1 and Table 1). There was a statistically significant interaction for the secondary outcome of 
having AD at last time of examination or questioning at 7 years of age (ADcurrent), in the direction of increased 
risk of AD from cat exposure in children with FLG mutations (OR 1.36 (95% CI 1.02-1.82) I2% 8.6), but this 
was not statistically significant after adjustment for multiple testing. The FLG-stratified analyses showed a 
trend towards cat exposure being a risk factor in children with FLG mutations and a protective factor in children 
without FLG mutations (Figure 1 and Supplementary Table 3). No interaction was found for the other 
secondary outcome ‘ADever’ (OR 1.06 (95% CI 0.82-1.37), I2%  0.0) 
 
Discussion 
We found no interaction between cat exposure in infancy and mutations in FLG on ‘early-onset AD’ or ‘AD 
ever’. A nominally significant interaction in the expected direction was found for the secondary outcome 
‘current AD’ at 7 years of age, but this did not survive adjustment for multiple testing. 
 
A particular study strength is the large number of independent birth cohorts with prospective assessment of 
exposure and outcomes. Most cohorts had genotype information for the 4 most common FLG mutations 
ensuring a high degree of correct classification. AD diagnoses were based on questionnaire data in most  
cohorts, potentially reducing diagnostic specificity. Since AD is a chronic and relapsing disease, short episodes 
of other eczemas, e.g. due to irritant or allergic contact dermatitis, may be suspected of being AD by parents 
and caregivers, in particular in the first years of life where flexural accentuation is not yet occurring. One may 
argue that AD measured at 7 years of age is expected to have a higher specificity due to flexural involvement. 




interaction. Cat exposure was only assessed around birth, and it is possible that later exposure to cat could have 
an unmeasured effect on AD. Similar, the extent of cat exposure might vary between studies and families. 
Other environmental factors were not included since covariate availability differed between the cohorts. 
Reverse causality cannot be excluded, as families who had experienced atopic disease might have avoided 
having pets to prevent allergic disease in their (next) child. However, one would expect families with FLG 
mutations, and thereby increased risk of eczema, to avoid cat ownership, which would tend towards an apparent 
protective effect of having a cat.  
 
No association between cat ownership and AD was found in another meta-analysis of 13 studies (relative risk 
0.94 (95%CI 0.76-1.16)).7 When a compelling gene-environment interaction was observed between FLG 
mutations and cat ownership on the risk of early-onset AD in birth cohorts, it raised the possibility that 
preventive measures against pediatric AD could be identified by taking the genetic susceptibility into account.3, 
4 The COPSAC2000 study, which provided the basis for the previous report of interaction between cat and 
FLG mutations, 3 benefited from close follow-up of children, and  high AD diagnostic accuracy, whereas most 
birth cohorts in the present meta-analysis used questionnaires, potentially leading to misclassification. 
 
No pathomechanism has been established for the proposed association between cat ownership and AD in FLG 
mutation carriers. Possibly, very small cat allergens might penetrate into the viable layers of the epidermis, 
where they can exert immune effects.8 Previous studies demonstrating increased risk of peanut allergy FLG 
mutation carriers, also suggest increased peanut allergen skin penetration. 9 Another explanation could be an 
effect of cat exposure on the gut microbiome of mothers and children. However, the absence of filaggrin 
protein expression in the gut argues against this.  
 
In conclusion, this meta-analysis could not confirm an interaction between cat exposure in infancy and FLG 
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Table 1. Baseline characteristics of participants in birth cohorts. 
 
 
*INMA sub cohorts: VAL, SAB, MEN  
** please see supplementary Table 1 for further details.  
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Figure 1. Interaction between cat exposure and common FLG mutations in relation to a) Early onset atopic 
dermatitis, b) Current atopic dermatitis and c) atopic dermatitis in the first 7 years of life.  
 
 
 
 
 
 
 
